OBJECTIVE To evaluate the safety and efficacy of long-term treatment of psoriasis with etanercept, 50 mg twice weekly. DESIGN, SETTING, AND PATIENTS A phase 3, randomized, double-blind trial with an open-label extension. A total of 618 adult patients with moderate to severe plaque psoriasis were studied at 39 medical centers in the United States and Canada from May 23, 2003, through June 22, ...

Study population The study population comprised a hypothetical cohort of patients with moderate-to-severe psoriasis. Three sub-groups of patients were considered on the basis of disease severity, as represented by two scores, the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI). The three sub-groups were PASI and DLQI greater than 10, PASI and DLQI greater ...

BACKGROUND Poor self-assessed mental health appears to be related to the severity of psoriasis. OBJECTIVE To evaluate the impact of psoriasis severity on mood and anxiety disorders. METHODS A prospective, observational, multicenter study was conducted by 123 dermatologists in Spain. Patients (n=164; mean [SD] age, 45.11 [13.92] years; 60.8% males) with moderate to severe psoriasis were eval...

BACKGROUND Chronic plaque-type psoriasis is a major dermatosis, but a significant question is still unanswered: What defines severity in chronic plaque-type psoriasis? While objective assessments like the Psoriasis Area and Severity Index (PASI) have frequently been used in clinical trials, quality of life (QOL) questionnaires are currently becoming more and more popular. OBJECTIVE This artic...

BACKGROUND A wide variety of psoriasis assessment tools have been proposed to evaluate the severity of psoriasis in clinical trials and daily practice. The most frequently used clinical instrument is the psoriasis area and severity index (PASI); however, none of the currently published severity scores used for psoriasis meets all the validation criteria required for an ideal score. OBJECTIVES...

BACKGROUND In the phase III double-blind Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2, apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in moderate to severe psoriasis. OBJECTIVE We sought to evaluate efficacy of apremilast in nail/scalp psoriasis in ESTEEM 1 and 2. METHODS A total of 1255 patients were randomized (2:1)...

BACKGROUND There are no systemic therapies approved in the United States to treat pediatric psoriasis. OBJECTIVE We sought to evaluate long-term safety and efficacy of etanercept in children and adolescents with moderate to severe plaque psoriasis. METHODS This 5-year, open-label extension study enrolled patients aged 4 to 17 years who had participated in a 48-week parent study. End points ...